Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET

Molecular Cancer Therapeutics · Published 2026-05-08 · DOI 10.1158/1535-7163.mct-25-0610

Authors being retrieved — see the publisher record. https://doi.org/10.1158/1535-7163.mct-25-0610

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Selected Articles from This Issue · Molecular Cancer Therapeutics · 2026 · Same journal
• RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model · Molecular Cancer Therapeutics · 2026 · Same journal
• HDAC Inhibition Unlocks Tumor Plasticity and Enhances Immunotherapy Response in Myc-Driven Small Cell Lung Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma · Molecular Cancer Therapeutics · 2026 · Same journal
• Selected Articles from This Issue · Molecular Cancer Therapeutics · 2026 · Same journal
• Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Mutant-Selective T-cell Receptor Therapy for Solid Tumors · Molecular Cancer Therapeutics · 2026 · Same journal
• Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers · Molecular Cancer Therapeutics · 2026 · Same journal
• PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Fedratinib Induces Nonclassical G2–M Arrest via Mitotic Kinase Inhibition and Synergizes with Mitomycin C to Suppress Pancreatic Ductal Adenocarcinoma · Molecular Cancer Therapeutics · 2026 · Same journal